STAT3 and STAT6 polymorphisms predict the severity of adverse reactions in Chinese NSCLC patients receiving EGFR-TKIs therapy

References

• Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016. J Nation Cancer Center. 2022;2(1):1–9.
   Google Scholar
• Friedlaender A, Addeo A, Russo A, et al. Targeted therapies in early stage NSCLC: hype or hope? IJMS. 2020;21(17):6329.
   Google Scholar
• He Q, Liu J, Cai X, et al. Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations. Transl Lung Cancer Res. 2021;10(11):4120–4129.
   PubMed Web of Science ®Google Scholar
• Sankar K, Gadgeel SM, Qin A. Molecular therapeutic targets in non-small cell lung cancer. Expert Rev Anticancer Ther. 2020;20(8):647–661.
   PubMed Web of Science ®Google Scholar
• Gelatti ACZ, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer. 2019;137:113–122.
   PubMed Web of Science ®Google Scholar
• Shah RR, Shah DR. Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in oncology. Drug Saf. 2019;42(2):181–198.
   PubMed Web of Science ®Google Scholar
• Cheng H, Liu H, Du Q, et al. Efficacy and safety of domestic and imported gefitinib in patients with advanced non-small cell lung cancer. Ann Palliat Med. 2021;10(1):10–15.
   PubMed Web of Science ®Google Scholar
• Du R, Yang H, Zhou H, et al. The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy. BMC Cancer. 2022;22(1):491.
   PubMed Web of Science ®Google Scholar
• Chan JC, Lee YH, Liu CY, et al. A correlational study of skin toxicity and quality of life in patients with advanced lung cancer receiving targeted therapy. J Nurs Res. 2019;27(6):e51.
   PubMedGoogle Scholar
• Gao Y, Luo L, Xie Y, et al. PYCR1 knockdown inhibits the proliferation, migration, and invasion by affecting JAK/STAT signalling pathway in lung adenocarcinoma. Mol Carcinog. 2020;59(5):503–511.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Shahda S, Beck T, et al. A phase Ib/II study of the JAK1 inhibitor, itacitinib, plus nab-Paclitaxel and gemcitabine in advanced solid tumours. Oncologist. 2019;24(1):14–e10.
   PubMed Web of Science ®Google Scholar
• Margolin K, Morishima C, Velcheti V, et al. Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumours. Clin Cancer Res. 2018;24(22):5552–5561.
   PubMed Web of Science ®Google Scholar
• Jung KB, Kwon O, Lee MO, et al. Blockade of STAT3 causes severe in vitro and in vivo maturation defects in intestinal organoids derived from human embryonic stem cells. J Clin Med. 2019;8(7):976.
   Web of Science ®Google Scholar
• Salas A, Hernandez-Rocha C, Duijvestein M, et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(6):323–337.
   PubMed Web of Science ®Google Scholar
• Liu T, Jin H, Ullenbruch M, et al. Regulation of found in inflammatory zone 1 expression in bleomycin-induced lung fibrosis: role of IL-4/IL-13 and mediation via STAT-6. J Immunol. 2004;173(5):3425–3431.
   PubMed Web of Science ®Google Scholar
• Milara J, Hernandez G, Ballester B, et al. The JAK2 pathway is activated in idiopathic pulmonary fibrosis. Respir Res. 2018;19(1):24.
   PubMedGoogle Scholar
• Jia R, Oda S, Tsuneyama K, et al. Establishment of a mouse model of troglitazone-induced liver injury and analysis of its hepatotoxic mechanism. J Appl Toxicol. 2019;39(11):1541–1556.
   PubMed Web of Science ®Google Scholar
• Jaruga B, Hong F, Sun R, et al. Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: up-regulating eotaxins and IL-5 and recruiting leukocytes. J Immunol. 2003;171(6):3233–3244.
   PubMed Web of Science ®Google Scholar
• Dai L, Zhang D, Qian Y, et al. STAT6 rs324015 gene polymorphism increases ulcerative colitis risk: a case-control study. Pharmgenomics Pers Med. 2021;14:101–107.
   PubMed Web of Science ®Google Scholar
• Zandi M, Moghaddam VA, Salehi Z, et al. The impact of STAT3 rs1053005 variation on type 1 diabetes mellitus susceptibility: association study and in silico analysis. Immunol Invest. 2022;51(6):1908–1919. Aug
   PubMed Web of Science ®Google Scholar
• Bai M, Wu ZZ, Huang YL, et al. STAT3 activates the transcription of lncRNA NR2F1-AS1 to promote the progression of melanoma via regulating the miR-493-5p/GOLM1 axis. J Gene Med. 2021;23(7):e3338. Jul
   PubMed Web of Science ®Google Scholar
• Abd El-Aziz A, El-Desouky MA, Shafei A, et al. Influence of pentoxifylline on gene expression of PAG1/miR-1206/SNHG14 in ischemic heart disease. Biochem Biophys Rep. 2021;25:100911. Mar
   PubMedGoogle Scholar
• Wang F, Huang G, Shen L, et al. Genetics and functional mechanisms of STAT3 polymorphisms in human tuberculosis. Front Cell Infect Microbiol. 2021;11:669394.
   PubMed Web of Science ®Google Scholar
• Lee YL, Yen JJ, Hsu LC, et al. Association of STAT6 genetic variants with childhood atopic dermatitis in Taiwanese population. J Dermatol Sci. 2015;79(3):222–228.
   PubMed Web of Science ®Google Scholar
• Schedel M, Frei R, Bieli C, et al. An IgE-associated polymorphism in STAT6 alters NF-kappaB binding, STAT6 promoter activity, and mRNA expression. J Allergy Clin Immunol. 2009;124(3):583–589, 9.e1-6.
   PubMed Web of Science ®Google Scholar
• Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15(2):97–98.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang Z, He Z, et al. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 2009;19(4):519–523.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957.
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–2388.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–128.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246.
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Liam CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26(9):1883–1889.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–3334.
   PubMed Web of Science ®Google Scholar
• Zhang H, Watanabe R, Berry GJ, et al. Inhibition of JAK-STAT signalling suppresses pathogenic immune responses in medium and large vessel vasculitis. Circulation. 2018;137(18):1934–1948.
   PubMed Web of Science ®Google Scholar
• Ohmori T, Yamaoka T, Ando K, et al. Molecular and clinical features of EGFR-TKI-associated lung injury. Int J Mol Sci. 2021;22(2):792.
   Web of Science ®Google Scholar
• Montero P, Milara J, Roger I, et al. Role of JAK/STAT in interstitial lung diseases; molecular and cellular mechanisms. Int J Mol Sci. 2021;22(12):6211.
   Web of Science ®Google Scholar
• Ling L, Zhang SH, Zhi LD, et al. MicroRNA-30e promotes hepatocyte proliferation and inhibits apoptosis in cecal ligation and puncture-induced sepsis through the JAK/STAT signalling pathway by binding to FOSL2. Biomed Pharmacother. 2018;104:411–419.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wang P, Lei L, et al. Overexpression of miR-142-5p inhibits the progression of nonalcoholic steatohepatitis by targeting TSLP and inhibiting JAK-STAT signalling pathway. Aging (Albany NY). 2020;12(10):9066–9084.
   PubMedGoogle Scholar
• Li Z, Li J, Zhang F, et al. Antidiarrheal effect of Sechang-Zhixie-San on acute diarrhea mice and network pharmacology deciphering its characteristics and potential mechanisms. Evid Based Complement Alternat Med. 2020;2020:8880298.
   PubMed Web of Science ®Google Scholar
• Gotthardt D, Trifinopoulos J, Sexl V, et al. JAK/STAT cytokine signalling at the crossroad of NK cell development and maturation. Front Immunol. 2019;10:2590.
   PubMed Web of Science ®Google Scholar
• Ciechanowicz P, Rakowska A, Sikora M, et al. JAK-inhibitors in dermatology: current evidence and future applications. J Dermatolog Treat. 2019;30(7):648–658.
   PubMed Web of Science ®Google Scholar
• Mullan KA, Anderson A, Illing PT, et al. HLA-associated antiepileptic drug-induced cutaneous adverse reactions. Hla. 2019;93(6):417–435.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li X, An X, et al. Continuous exposure of PM2.5 exacerbates ovalbumin-induced asthma in mouse lung via a JAK-STAT6 signalling pathway. Adv Clin Exp Med. 2020;29(7):825–832.
   PubMed Web of Science ®Google Scholar
• Miyauchi K, Ki S, Ukai M, et al. Essential role of STAT3 signalling in hair follicle homeostasis. Front Immunol. 2021;12:663177.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Umehara Y, Yue H, et al. The antimicrobial peptide human β-Defensin-3 accelerates wound healing by promoting angiogenesis, cell migration, and proliferation through the FGFR/JAK2/STAT3 signalling pathway. Front Immunol. 2021;12:712781.
   PubMed Web of Science ®Google Scholar
• Simon LS, Taylor PC, Choy EH, et al. The jak/STAT pathway: a focus on pain in rheumatoid arthritis. Semin Arthritis Rheum. 2021;51(1):278–284.
   PubMed Web of Science ®Google Scholar
• Xin P, Xu X, Deng C, et al. The role of JAK/STAT signalling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210.
   PubMed Web of Science ®Google Scholar
• Verdeil G, Lawrence T, Schmitt-Verhulst AM, et al. Targeting STAT3 and STAT5 in Tumor-Associated immune cells to improve immunotherapy. Cancers (Basel). 2019;11(12):1832.
   PubMed Web of Science ®Google Scholar
• Liu T, Song J, Zhang M, et al. Interleukin-21 receptor gene polymorphism is associated with hepatitis B virus-related hepatocellular carcinoma in chinese patients. J Clin Lab Anal. 2019;33(5):e22860.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang C, Liu Z, et al. Host genetic determinants of hepatitis B virus infection. Front Genet. 2019;10:696.
   PubMed Web of Science ®Google Scholar
• Song Y, Yang X, Shen Y, et al. STAT3 signalling pathway plays importantly genetic and functional roles in HCV infection. Mol Genet Genomic Med. 2019;7(8):e821.
   PubMed Web of Science ®Google Scholar
• Tsilifis C, Freeman AF, Gennery AR. STAT3 Hyper-IgE syndrome-an update and unanswered questions. J Clin Immunol. 2021;41(5):864–880.
   PubMed Web of Science ®Google Scholar
• Chen CH, Lee YL, Wu MH, et al. Sex-moderated interactions between IL4/IL13 pathway genes and prenatal environment on cord blood IgE levels. Clin Exp Allergy. 2019;49(8):1128–1138.
   PubMed Web of Science ®Google Scholar
• Calonga-Solís V, Amorim LM, Farias TDJ, et al. Variation in genes implicated in B-cell development and antibody production affects susceptibility to pemphigus. Immunology. 2021;162(1):58–67.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study. J Am Acad Dermatol. 2021;85(4):854–862.
   PubMed Web of Science ®Google Scholar
• Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020;145(2):572–582.
   PubMed Web of Science ®Google Scholar